2014

MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCall's Microscope

LONDON, April 23, 2013 /PRNewswire/ --

Following the expiration of patents on several blockbuster drugs, big pharma companies have been looking to boost their product pipeline. While in-house research and development will be crucial to boost product pipeline, major pharma companies may also benefit by collaborating with emerging biotechnology companies that have developed or are developing potential blockbuster drugs. Biotechnology stocks ended mostly lower on Monday even as the broad market rose for a second successive trading session. Among the major movers in the biotechnology sector yesterday were MannKind Corporation (NASDAQ: MNKD), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Galena Biopharma Inc. (NASDAQ: GALE), and Novavax Inc. (NASDAQ: NVAX). StockCall has released full comprehensive research on MNKD, ARIA, ZIOP, GALE, and NVAX and these free technical analyses can be downloaded by signing up at

http://www.stockcall.com/technicalanalysis

Shares of MannKind Corporation edged lower on Monday. The stock traded between $3.86 and $4.07 before finishing the day 0.50% lower at $3.99 on volume of 2.70 million. MannKind's shares are currently trading more than 11.30% below their 52-week high. The stock has had an excellent run so far in 2013, gaining more than 72.70%. Shares of MNKD are currently trading well above their 50-day and 200-day moving averages which is a bullish signal. Free technical analysis on MNKD available by signing up at

http://www.StockCall.com/MNKD042313.pdf

Shares of Ariad Pharmaceuticals Inc. fell sharply yesterday even as the broad market posted gains. The stock closed 1.02% lower at $18.51 on above average volume of 3.59 million. Despite the losses seen on Monday, Ariad Pharma's shares are still up more than 1.40% in the last three trading sessions. Year-to-date, the stock is down nearly 3.50%. However, the biotech company's shares have seen a series of highs over the past few trading sessions, which suggests that market sentiment has turned bullish on the stock. Register today and access the free research on ARIA at

http://www.StockCall.com/ARIA042313.pdf

ZIOPHARM Oncology Inc.'s shares struggled in Monday's trading session, reversing some of the recent gains. The stock fell to an intra-day low of $1.67 before finishing the day 2.33% lower at $1.68 on volume of 760,400. Despite the losses yesterday, ZIOPHARM's shares gained more than 4.30% in the last three sessions. The stock's MACD has just crossed above the signal line, which suggests that market sentiment has once again turned bullish on ZIOP. Year-to-date, the company's shares are down nearly 60%. The free report on ZIOP can be downloaded by signing up now at

http://www.StockCall.com/ZIOP042313.pdf

Galena Biopharma Inc. shares fell sharply yesterday. The stock traded between $2.30 and $2.46 before finishing the day 3.33% lower at $2.32 on above average volume of 2.12 million. Despite the losses, Galena's shares are still trading close to their 52-week high of $2.60. The stock has had an excellent run so far in 2013, jumping more than 51%, compared to a gain of more than 9.50% for the S&P 500. Free report on GALE can be accessed by registering at

http://www.StockCall.com/GALE042313.pdf

Novavax Inc.'s shares edged higher in Monday's trading session, extending their gains from previous trading session. The stock closed 0.40% higher at $2.51 on volume of 919,000, taking its gains in the last three sessions to over 2.60%. Novavax's shares are currently trading well above their 50-day and 200-day moving averages. The stock's MACD, however, recently crossed below the signal line, which is a bearish signal. Register with StockCall and download the research on NVAX for free at

http://www.StockCall.com/NVAX042313.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

http://www.stockcall.com  

SOURCE StockCall.com




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.